SilcsBio's parent company, Early Charm, has a job opening to work with SilcsBio and other portfolio companies focused on Drug Design and Machine Vision.   Immediate Job Opening   Full-Stack Developer Deep Tech Applications   July 27, 2021   What we do: Early Charm creates, owns, and operates businesses that convert science into revenue. We [...]

FOR IMMEDIATE RELEASE:   SilcsBio is Selected by the NIH to 2021 BIO Digital’s Innovation Zone, June 10-11 and 14-18   SilcsBio’s Sunhwan Jo to attend BIO Digital with focus on SilcsBio's expertise in fragment-based drug design, MD simulations, and computational drug discovery   June 8, 2021, Baltimore, MD – SilcsBio, a technology company that develops [...]

FOR IMMEDIATE RELEASE:   SilcsBio Joins with NIST and Pharma Partner In Validating SILCS Technology for Biologics Formulation   Scientific collaboration demonstrates effective computational method for stabilizing biologic therapeutics such as antibodies   December 16, 2020, Baltimore, MD – SilcsBio, LLC, a technology company that develops and markets software and services for structure-based drug design, today announced members [...]

SilcsBio and Dalriada to tap areas of expertise in drug design and development to accelerate clients’ programs in development of therapeutic treatments against diseases with unmet needs, initiated with COVID-19 FOR IMMEDIATE RELEASE: June 11, 2020, Baltimore, MD and Toronto, ON – SilcsBio, a technology company that develops innovative software and provides services for structure-based [...]

GEn1E Lifesciences, a Y Combinator-Backed Company, Granted Exclusive License for University of Maryland, Baltimore Drug Portfolio Compound Tuesday, December 3, 2019 PALO ALTO, Calif. and BALTIMORE, Dec. 3, 2019 /PRNewswire/ -- GEn1E Lifesciences Inc., a Y Combinator-backed biotech startup focused on curing inflammatory and age-related diseases, announced today that it has acquired an exclusive, worldwide and [...]